Annals of Oncology最新文献

{"title":"The next-generation of nectin-4 targeted therapies","authors":"C. Pobel , Y. Loriot","doi":"10.1016/j.annonc.2025.06.002","DOIUrl":"10.1016/j.annonc.2025.06.002","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 8","pages":"Pages 849-850"},"PeriodicalIF":56.7,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144623808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the Letter to the Editor by Szarpak et al.","authors":"I.A. van Assche , E. Huis In ‘t Veld , K. van Calsteren , J. Lemiere , T. Salaets , M.M. van den Heuvel-Eibrink , F. Amant","doi":"10.1016/j.annonc.2025.06.011","DOIUrl":"10.1016/j.annonc.2025.06.011","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 10","pages":"Pages 1235-1237"},"PeriodicalIF":65.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144615952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term development after maternal cancer treatment: some reassurance but still open questions","authors":"S. Loibl , B. Winter , M. Reinisch","doi":"10.1016/j.annonc.2025.07.001","DOIUrl":"10.1016/j.annonc.2025.07.001","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 9","pages":"Pages 1003-1004"},"PeriodicalIF":65.4,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer","authors":"M.P. Arenhardt , A. Nogueira-Rodrigues","doi":"10.1016/j.annonc.2025.06.016","DOIUrl":"10.1016/j.annonc.2025.06.016","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 10","pages":"Page 1220"},"PeriodicalIF":65.4,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","authors":"K.C. Kähler ,&nbsp;J.C. Hassel ,&nbsp;M. Ziemer ,&nbsp;P. Rutkowski ,&nbsp;F. Meier ,&nbsp;L. Flatz ,&nbsp;C. Gaudy-Marqueste ,&nbsp;L. Zimmer ,&nbsp;M. Santinami ,&nbsp;F. Russano ,&nbsp;I. von Wasielewski ,&nbsp;T.K. Eigentler ,&nbsp;M. Maio ,&nbsp;I. Zalaudek ,&nbsp;S. Haferkamp ,&nbsp;P. Quaglino ,&nbsp;J. Welzel ,&nbsp;C. Röcken ,&nbsp;A. Enk ,&nbsp;J.-C. Simon ,&nbsp;A. Hauschild","doi":"10.1016/j.annonc.2025.06.014","DOIUrl":"10.1016/j.annonc.2025.06.014","url":null,"abstract":"<div><h3>Background</h3><div>This phase III trial assessed daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant treatment for patients with clinically detectable stage IIIB/C melanoma [American Joint Committee on Cancer (AJCC) version 7].</div></div><div><h3>Patients and methods</h3><div>Patients were randomized to weekly intralesional daromun administrations (13 million IU of L19IL2 and 400 μg of L19TNF) for 4 weeks followed by surgery, or upfront surgery. Pretreatment with approved adjuvant agents was allowed. The primary endpoint was recurrence-free survival (RFS): events were disease recurrence or death from any cause after complete surgical tumor resection (<span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> NCT02938299).</div></div><div><h3>Results</h3><div>A total of 246 patients were randomized and included in the intention-to-treat analysis: 74% had undergone two or more prior surgical resections and 35% had received prior systemic therapy. At a median follow-up of 21 months, the neoadjuvant group (<em>n</em> = 122) had a significantly longer RFS than the upfront surgery group (<em>n</em> = 124), with a median RFS of 16.7 months and 6.8 months, respectively [hazard ratio (HR) 0.59, 95% confidence interval (CI 0.41-0.86), <em>P</em> = 0.005, log-rank test]. The risk of distant recurrence was reduced by 40% in the neoadjuvant arm (HR 0.60, 95% CI 0.37-0.95, <em>P</em> = 0.029). Grade ≥3 treatment-related adverse events (TRAEs) were 6.7% in the surgery-alone arm and 27.1% in the daromun arm, mostly injection site reactions.</div></div><div><h3>Conclusions</h3><div>Neoadjuvant daromun resulted in a significantly longer RFS than upfront surgery in patients with locally advanced melanoma. TRAEs were transient and manageable. Neoadjuvant daromun is a new therapeutic option for patients with stage III melanoma, including those with locoregional recurrence after surgery and previous adjuvant therapy.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 10","pages":"Pages 1166-1177"},"PeriodicalIF":65.4,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRAS^G12C inhibitors.","authors":"F Castet, T V Tian, T Macarulla","doi":"10.1016/j.annonc.2025.06.018","DOIUrl":"10.1016/j.annonc.2025.06.018","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancer.","authors":"A Mamann, Y Pradat, F C Bidard, S Delaloge, L Cabel, I Faull, S Marques, T Bachelot, F Dalenc, T de la Motte Rouge, B Pistilli, J Samaniego, J S Frenel, C Levy, J M Ferrero, R Sabatier, S Ladoire, C Chakiba, A C Hardy, J Lemonnier, Y Mahi, F Andre, P H Cournede, S Michiels, E Bernard","doi":"10.1016/j.annonc.2025.06.015","DOIUrl":"10.1016/j.annonc.2025.06.015","url":null,"abstract":"<p><strong>Background: </strong>Patients with advanced estrogen receptor-positive, HER2-negative breast cancer commonly develop resistance to treatment with hormone therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Responders cannot be distinguished from nonresponders after the first cycle of treatment under current practice. We assessed circulating tumor DNA (ctDNA) measures at early timepoints as prognostic markers.</p><p><strong>Patients and methods: </strong>Paired plasma samples were collected at baseline and early on-treatment (median 28 days) from 369 patients with advanced ER-positive/HER2-negative breast cancer treated in the PADA-1 trial with hormone therapy and a CDK4/6 inhibitor. Cell-free DNA was profiled with a 497-gene panel (Guardant360 LDT).</p><p><strong>Results: </strong>Baseline ctDNA levels, including the mean variant allele frequency (VAF) [progression-free survival (PFS) hazard ratio (HR) 1.07, 95% confidence interval (CI) 1.05-1.09), P < 0.001; overall survival (OS) HR 1.08, 95% CI 1.05-1.11, P < 0.001] and the number of driver somatic mutations (PFS HR 1.13, 95% CI 1.07-1.19, P < 0.001; OS HR 1.16, 95% CI 1.07-1.24, P < 0.001) were prognostic. Early on-treatment ctDNA dynamics were also associated with outcomes, including the number of driver somatic mutations with VAF > 0.5% at both timepoints (PFS HR 1.39, 95% CI 1.27-1.53, P < 0.001; OS HR 1.51, 95% CI 1.35-1.68, P < 0.001) and the number of driver somatic mutations with a VAF increase (PFS HR 1.31, 95% CI 1.19-1.44, P < 0.001; OS HR 1.10, 95% CI 1.02-1.18, P = 0.02). A ctDNA-based risk model incorporating baseline and dynamic ctDNA features was independently prognostic from RECIST in multivariable models (test set: OS HR 4.10, 95% CI 1.93-8.72, P < 0.001; PFS HR 1.86, 95% CI 1.16-2.97, P = 0.009). The integration of ctDNA features into a clinical model improved survival discrimination for PFS [C-index 64.7% (± 2.5%) for a ctDNA and clinical model versus 59.3% (± 2.2%) for a clinical-only model, P = 0.027] and for OS [C-index 70.0% (± 3.4%) versus 60.3% (± 4.2%), P = 0.035].</p><p><strong>Conclusions: </strong>Early on-treatment evolution of ctDNA is prognostic for both PFS and OS in advanced ER-positive/HER2-negative breast cancer. A ctDNA-based risk model improves upon traditional RECIST and clinical parameters, advocating for ctDNA as a prognostic biomarker in clinical practice.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":65.4,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"80P Tumor immune microenvironment in young, multi-ethnic colorectal cancer patients","authors":"M.E. Salem ,&nbsp;P. Zhang ,&nbsp;N. Steuerwald ,&nbsp;A. Patrick ,&nbsp;F. Guo ,&nbsp;L. Liang ,&nbsp;L. Miller ,&nbsp;S. Chai ,&nbsp;J. Hill ,&nbsp;J. Hwang ,&nbsp;K. Kadaki ,&nbsp;W. Zhang ,&nbsp;D. Foureau","doi":"10.1016/j.annonc.2025.05.092","DOIUrl":"10.1016/j.annonc.2025.05.092","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S41"},"PeriodicalIF":56.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"32P A novel imaging biomarker, quantitative vessel tortuosity, captures the antiangiogenic effect of fruquintinib in metastatic colorectal cancer","authors":"S. Lonardi ,&nbsp;O. Yardibi ,&nbsp;N.A. Dasari ,&nbsp;L. Chen ,&nbsp;V. Sundaresan ,&nbsp;A. Madabhushi ,&nbsp;J. Narang","doi":"10.1016/j.annonc.2025.05.044","DOIUrl":"10.1016/j.annonc.2025.05.044","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S19"},"PeriodicalIF":56.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"21P Real-world genomic profiles in patients with HER2-positive metastatic colorectal cancer","authors":"Y. Matsubara ,&nbsp;H. Bando ,&nbsp;Y. Nakamura ,&nbsp;T. Misumi ,&nbsp;D. Ng ,&nbsp;E. Tajima ,&nbsp;H. Pittell ,&nbsp;C. Cho-Phan ,&nbsp;T. Yoshino ,&nbsp;A. Ohtsu","doi":"10.1016/j.annonc.2025.05.033","DOIUrl":"10.1016/j.annonc.2025.05.033","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S14"},"PeriodicalIF":56.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}